Hejnova Lucie, Drastichova Zdenka, Boroš Almos, Hrdlicka Jaroslav, Behuliak Michal, Neckar Jan, Zicha Josef, Novotny Jiri
Department of Physiology, Faculty of Science, Charles University, Prague, Czechia.
Institute of Physiology, Czech Academy of Sciences, Prague, Czechia.
Front Cardiovasc Med. 2024 Sep 16;11:1390547. doi: 10.3389/fcvm.2024.1390547. eCollection 2024.
The consequences at the molecular level and the mechanisms involved in a possible cardioprotective effect of antihypertensive treatment are not yet fully understood. Here, the efficacy of pyridostigmine (PYR) and trandolapril (TRA) as antihypertensive and antihypertrophic agents was investigated and compared in hypertensive SHR and normotensive WKY rats. In parallel, we investigated the effects of these drugs on myocardial β-adrenergic and cholinergic signaling pathways and protein expression profiles.
Age-matched male SHR and WKY rats were chronically (8 weeks) treated with PYR or TRA in drinking water. Blood pressure (BP) and heart rate (HR) were monitored telemetrically prior to tissue sampling for biochemical analysis. Baroreceptor reflex sensitivity (BRS) and methylatropine HR response as a measure of vagal tone were evaluated in separate groups of animals.
PYR slightly lowered BP and HR in SHR rats during the dark phase of the day, while TRA effectively reduced BP during the light and dark phases without affecting HR. PYR enhanced BRS and improved vagal tone. There were no significant alterations in myocardial β-adrenergic and cholinergic signaling, with the exception of decreased forskolin-stimulated adenylyl cyclase (AC) activity in SHR rats, which was restored by TRA. Proteomic analysis revealed numerous differences induced by both treatments. Notable were changes in TGFβ-related signaling pathways as well as proteins involved in modifying hemodynamic parameters and cardiac hypertrophy.
PYR is able to slightly decrease BP and HR in SHR rats but effectively increase BRS through vagal potentiation. The specific differences in protein expression profiles in rat myocardium induced by treatment with PYR and TRA reflect different mechanisms of action of these two agents at the molecular level.
抗高血压治疗可能产生的心脏保护作用在分子水平上的后果及相关机制尚未完全明确。在此,我们在高血压自发性高血压大鼠(SHR)和正常血压的Wistar-Kyoto大鼠(WKY)中研究并比较了吡啶斯的明(PYR)和群多普利(TRA)作为抗高血压和抗肥厚药物的疗效。同时,我们研究了这些药物对心肌β-肾上腺素能和胆碱能信号通路以及蛋白质表达谱的影响。
将年龄匹配的雄性SHR和WKY大鼠通过饮用水长期(8周)给予PYR或TRA治疗。在采集组织进行生化分析之前,通过遥测技术监测血压(BP)和心率(HR)。在单独的动物组中评估压力感受器反射敏感性(BRS)和甲基阿托品心率反应以衡量迷走神经张力。
PYR在SHR大鼠白天的暗期略微降低BP和HR,而TRA在明期和暗期均有效降低BP但不影响HR。PYR增强了BRS并改善了迷走神经张力。心肌β-肾上腺素能和胆碱能信号无明显改变,但SHR大鼠中福斯高林刺激的腺苷酸环化酶(AC)活性降低,TRA可使其恢复。蛋白质组学分析揭示了两种治疗均诱导了许多差异。值得注意的是TGFβ相关信号通路以及参与调节血流动力学参数和心脏肥大的蛋白质的变化。
PYR能够使SHR大鼠的BP和HR略有降低,但通过增强迷走神经功能有效增加BRS。PYR和TRA治疗诱导的大鼠心肌蛋白质表达谱的特定差异反映了这两种药物在分子水平上不同的作用机制。